Project Coordinator: Deutsches Krebsforschungszentrum (DKFZ), DEU
Prof. Dr. Heinrich Kovar , Children´s Cancer Research Institute/Molecular Biology of Solid Tumours,
Medizinische Universität Wien (MUW), AUT
Zürich University (UZH), Roche (ROCHE), CHE
Charité Berlin (Charite), Bayer AG (BAY), EPO-Berlin-Buch GmbH (EPO), Oncotest (OT), DEU
Fundació Sant Joan de Déu Barcelona (FSJD), PharmaMar (PHARMAMAR), ESP
European consortium for Innovative Therapies for Children with Cancer (ITCC), Institute Gustave Roussy (IGR), XenTech, Institut Curie (IC), FRA
Institute for Cancer Research (ICR), Eli Lilly and Co (Eli Lilly), Pfizer (PFZ), GBR
Alleanza Contro il Cancro (ACC), ITA
Academic Medical Center (AMC), Prinses Maxima Center Utrecht (PMC), NDL
Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant solid tumors, usually after very intensive first-line therapy, curative treatment options are scarce. Preclinical drug testing to identify promising treatment options that match the molecular make-up of the tumor is hampered by the facts that i) molecular genetic data on pediatric solid tumors from relapsed patients and thus our understanding of tumor evolution and therapy resistance are very limited to date and ii) for many of the high-risk entities no appropriate and molecularly well characterized patient-derived models and/or genetic mouse models are currently available. Thus, quality-assured upfront preclinical testing of novel molecularly targeted compounds in a (saturated) repertoire of well-characterized models will establish the basis to increase therapeutic successes of these drugs in children with solid malignancies. Since these tumors are overall genetically much less complex than their adult counterparts, it is anticipated that it will be easier to identify powerful predictive biomarkers to allow for accurate matching of targets and drugs.
To address this high, as yet unmet clinical need, we have formed the ITCC-P4 consortium consisting of academic and commercial partners from 8 European countries and covering the full spectrum of qualifications needed for quality-assured preclinical drug development including expertise in patient derived models, histopathology, in vivo pharmacology, bioinformatics and data management, centralized testing capabilities, medical expertise regarding the entities in question, regulatory knowledge, and project management of large consortia.
With this consortium in a public-private partnership with the participating pharma companies we strongly believe to be ideally positioned to greatly expedite the development of more precise and efficacious drugs for children with malignant solid tumors.
Funded under the programme Innovative Medicines Initiative, call H2020-JTI-IMI2-2015-07, by the European Commission
Duration: 01.01.2017 – 31.12.2021